Phase 2
Completed N=73
Niclosamide for Mild to Moderate COVID-19
Source: ClinicalTrials.gov NCT04399356 ↗Enrolled (actual)
73
Serious AEs
0.0%
Results posted
Apr 2022
Primary outcomePrimary: Time to Respiratory Viral Clearance — 3.39; 3.44 Days
Summary
This study will evaluate the antihelmintic drug, Niclosamide, as a potential treatment for mild to moderate coronavirus disease 2019 (COVID-19).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Respiratory Viral Clearance |
3.39; 3.44 | — |
| SECONDARY Time to Fecal Viral Clearance |
6.12; 5.77 | — |
| SECONDARY Number of Participants With Progression to Severe COVID-19 Disease |
0; 1 | — |
| SECONDARY Number of Days to Resolution of a Fever |
10.2; 3.6 | — |
Eligibility Criteria
Inclusion Criteria
- Positive SARS-CoV-2 test by PCR
- No requirement of oxygen supplementation
- Ability to take oral medication
Exclusion Criteria
- Known allergic reactions to any components of Niclosamide medication
- Participation in another trial or use of any experimental treatment for COVID-19, including chloroquine, hydroxychloroquine, remdesivir, and lopinavir/ritonavir
- Hospitalization or requirement of hospitalization at the time of enrollment
Data sourced from ClinicalTrials.gov (NCT04399356). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.